Literature DB >> 10472510

Do heavy smokers benefit from higher dose nicotine patch therapy?

J D Killen1, S P Fortmann, L Davis, L Strausberg, A Varady.   

Abstract

Heavy smokers (N = 408, smoking more than 25 cigarettes/day) were randomized to receive high-dose (25 mg) or standard-dose (15 mg) nicotine patch therapy delivered during the daytime only (16 hr) for a period of 6 weeks. Treatment effects of each dose were similar. The percentages of participants not smoking at 2-, 6-, and 12-month follow-ups were 26 versus 20, 14 versus 16, and 14 versus 14 for the 15-mg and 25-mg doses, respectively. The higher dose was well tolerated, and adverse event profiles for both treatment doses were very similar. Stepwise Cox proportional hazards analyses indicated that initial postrandomization craving and baseline scores on the Center for Epidemiological Studies Depression Instrument predicted time-to-relapse during treatment; only initial craving predicted relapse over the entire study interval (12 months). The results of this trial do not support the routine use of higher dose nicotine patch therapy in the treatment of nicotine dependence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472510     DOI: 10.1037//1064-1297.7.3.226

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  28 in total

Review 1.  Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability.

Authors:  C T Sweeney; R V Fant; K O Fagerstrom; J F McGovern; J E Henningfield
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigation.

Authors:  Tai-Hing Lam; Abu Saleh M Abdullah; Sophia S C Chan; Anthony J Hedley
Journal:  Psychopharmacology (Berl)       Date:  2004-07-29       Impact factor: 4.530

3.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

4.  Relations between anhedonia and smoking motivation.

Authors:  Adam M Leventhal; Andrew J Waters; Christopher W Kahler; Lara A Ray; Steve Sussman
Journal:  Nicotine Tob Res       Date:  2009-07-01       Impact factor: 4.244

5.  Exploring refinements in targeted behavioral medicine intervention to advance public health.

Authors:  Abby C King; David F Ahn; Audie A Atienza; Helena C Kraemer
Journal:  Ann Behav Med       Date:  2008-06-21

Review 6.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

7.  Right anterior insula connectivity is important for cue-induced craving in nicotine-dependent smokers.

Authors:  Megan M Moran-Santa Maria; Karen J Hartwell; Colleen A Hanlon; Melanie Canterberry; Todd Lematty; Max Owens; Kathleen T Brady; Mark S George
Journal:  Addict Biol       Date:  2014-02-13       Impact factor: 4.280

8.  Effects of internet-based voucher reinforcement and a transdermal nicotine patch on cigarette smoking.

Authors:  Irene M Glenn; Jesse Dallery
Journal:  J Appl Behav Anal       Date:  2007

Review 9.  In vivo brain imaging of human exposure to nicotine and tobacco.

Authors:  Anil Sharma; Arthur L Brody
Journal:  Handb Exp Pharmacol       Date:  2009

10.  A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.

Authors:  Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker
Journal:  Arch Gen Psychiatry       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.